Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases-Reference-Cited by-同舟云学术

Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases

Published:2020-05-27 Issue: Volume:11 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Decara Juan,Rivera Patricia,López-Gambero Antonio Jesús,Serrano Antonia,Pavón Francisco Javier,Baixeras Elena,Rodríguez de Fonseca Fernando,Suárez Juan

Funder

Consejería de Salud, Junta de Andalucía

Instituto de Salud Carlos III

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference209 articles.

1. Molecular basis for gene-specific transactivation by nuclear receptors;Aagaard;Biochim. Biophys. Acta,2011

2. Inflammatory bowel disease;Abraham;N. Engl. J. Med.,2009

3. PPARgamma signaling and metabolism: the good, the bad and the future;Ahmadian;Nat. Med.,2013

4. The endogenous bioactive lipid prostaglandin D2-glycerol ester reduces murine colitis via DP1 and PPARgamma receptors;Alhouayek;FASEB J.,2018

5. Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease;Ananthakrishnan;Gut,2014

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anandamide: From modulation of neuronal excitation to antimicrobial activities—What is in common?;Anandamide in Health and Disease;2025

2. Bifidobacterium bifidum Strain BB1 Inhibits Tumor Necrosis Factor-α–Induced Increase in Intestinal Epithelial Tight Junction Permeability via Toll-Like Receptor-2/Toll-Like Receptor-6 Receptor Complex–Dependent Stimulation of Peroxisome Proliferator-Activated Receptor γ and Suppression of NF-κB p65;The American Journal of Pathology;2024-09

3. Long Non-Coding RNAs, Nuclear Receptors and Their Cross-Talks in Cancer—Implications and Perspectives;Cancers;2024-08-22

4. Application of PPAR Ligands and Nanoparticle Technology in Metabolic Steatohepatitis Treatment;Biomedicines;2024-08-16

5. Selected phytocannabinoids inhibit SN-38- and cytokine-evoked increases in epithelial permeability and improve intestinal barrier function in vitro;Toxicology in Vitro;2024-08